A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects with Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to perform two tests to test for two particular types of biomarkers (i.e. protein, DNA or RNA) in the body to see if someone might be suitable for a genetically changed T cell treatment.
The study will assess a subject's human leukocyte antigen (HLA) subtype and tumor antigen expression profile. Based on the results, it will be determined if a subject is eligible to be considered for Adaptimmune sponsored clinical trials testing the safety and efficacy of genetically changed T cells targeting specific tumor antigens.
- IRB Number: 1511715598 (ADP-0000-001)
- Research Study Identifier: TX5996
- Principal Investigator: Shadia Jalal, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required